Incyte Corporation
INCYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Incyte Corporation (INCY) is listed under Biotechnology. At a $25.22B market cap, Incyte Corporation ranks as a large-cap company within healthcare. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Market Cap
$25.22B
Beta
0.77
P/E (TTM)
15.85
P/E (Fwd)
14.00
EPS (TTM)
$7.85
EPS (Fwd)
$8.89
ROE
30.7%
ROA
16.8%
Cash
$4.54B
Total Debt
$38.3M
Free CF
$1.18B
52W Change
47.0%
Annual Financials
Cash vs Debt
Where INCY stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, INCY finished 18.91% above its 150-day moving average ($105.13) and 19.78% above its 200-day moving average ($104.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INCY overbought or oversold?
At the September 2, 2026 close, INCY's RSI(14) was 60.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $4.54B in cash and $38.3M in debt, INCY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $1.18B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 30.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 16.8% further supports the picture of efficient asset utilization. Revenue has grown from $3.39B (2022) to $5.14B (2025), reflecting a 51% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing INCY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.